Gimeracil
drugOn this page
Also known as Gimeracil component of teysunoGimeraciloGimestatSID50125750SID144206214SID170466048
Summary
Gimeracil (CHEMBL1730601) is a phase-3 clinical-stage small molecule; indicated across 35 conditions including colorectal adenocarcinoma and gastric adenocarcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 35 conditions
- Clinical trials: 4
- Chemistry: 145.54 Da · C5H4ClNO2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1730601 |
| Name | Gimeracil |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 54679224 |
| Molecular formula | C5H4ClNO2 |
| Molecular weight | 145.54 |
| InChIKey | ZPLQIPFOCGIIHV-UHFFFAOYSA-N |
SMILES: C1=C(C(=CNC1=O)Cl)O
IUPAC name: 5-chloro-4-hydroxy-1H-pyridin-2-one
Also known as: Gimeracil, Gimeracil component of teysuno, Gimeracilo, Gimestat, SID50125750, SID144206214, SID170466048, GIMERACIL, gimeracil
Patent coverage: 381 distinct patent families (1,200 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,060 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Alpha-1A adrenergic receptor.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
35 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| colorectal adenocarcinoma | 3 | MONDO:0005008 | EFO:0000365 |
| gastric adenocarcinoma | 3 | MONDO:0005036 | EFO:0000503 |
| exocrine pancreatic carcinoma | 3 | MONDO:0005192 | EFO:0002618 |
| carcinoma of esophagus | 3 | MONDO:0019086 | EFO:0002916 |
| gastric neoplasm | 3 | MONDO:0021085 | EFO:0003897 |
| colorectal neoplasm | 3 | MONDO:0005335 | EFO:0004142 |
| cholangiocarcinoma | 3 | MONDO:0019087 | EFO:0005221 |
| esophageal squamous cell carcinoma | 3 | MONDO:0005580 | EFO:0005922 |
| head and neck cancer | 3 | MONDO:0005627 | EFO:0006859 |
| adenocarcinoma | 3 | MONDO:0004970 | EFO:0000228 |
| pancreatic neoplasm | 3 | MONDO:0021040 | EFO:0003860 |
| gastric carcinoma | 3 | MONDO:0004950 | EFO:0000178 |
| malignant pancreatic neoplasm | 3 | MONDO:0009831 | EFO:1000359 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| breast neoplasm | 2 | MONDO:0021100 | EFO:0003869 |
| rectal cancer | 2 | MONDO:0006519 | EFO:1000657 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| neuroendocrine carcinoma | 2 | MONDO:0002120 | MONDO:0002120 |
| rectal neoplasm | 2 | MONDO:0002165 | MONDO:0044937 |
| pancreatic ductal adenocarcinoma | 2 | MONDO:0005184 | MONDO:0005184 |
| nasopharyngeal carcinoma | 2 | MONDO:0015459 | MONDO:0015459 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00503321 | PHASE2/PHASE3 | TERMINATED | Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma |
| NCT02008422 | PHASE3 | UNKNOWN | Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer |
| NCT02504229 | PHASE2 | UNKNOWN | DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment |
| NCT02749526 | PHASE2 | TERMINATED | Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: colorectal adenocarcinoma, gastric adenocarcinoma, exocrine pancreatic carcinoma, carcinoma of esophagus, gastric neoplasm, colorectal neoplasm, cholangiocarcinoma, esophageal squamous cell carcinoma, head and neck cancer, adenocarcinoma, pancreatic neoplasm, gastric carcinoma, malignant pancreatic neoplasm